Top Venture Capital Firms & Investors for Biotech Startups in 2025

The biotech sector experienced a major rebound in 2024, with venture funding surging after a slowdown in 2022–23. In the U.S. and Europe, biotech startups collectively raised $28.1 billion in venture capital, marking a 33% increase from the previous year’s $21.2 billion. This renewed confidence in biotech investment was characterized by larger funding rounds but fewer deals overall, signaling a shift toward high-conviction bets on select companies.

Investors play a critical role in the biotech ecosystem. They provide the necessary capital to fund research, development, and commercialization of new technologies. Understanding the landscape of biotech investment in 2024 can give startups a significant edge in attracting and securing the right partners. We have therefore listed the worlds all BioTech investors.

Leading Biotech Venture Capital Firms and Investors

Biotech remains dominated by sector-specialized investors, with several top-tier venture capital firms and corporate backers leading the largest deals in 2024.

Among the most active biotech VCs were Novo Holdings, Frazier Life Sciences, Arch Venture Partners, and Forbion Ventures, all of which played key roles in financing high-growth startups and emerging biopharma innovators.

In a sign of growing crossover between biotech and Silicon Valley, leading tech-focused funds are expanding into biotech investing. Andreessen Horowitz (a16z Bio Fund) and SoftBank made high-profile biotech bets in 2024, particularly in the AI-driven drug discovery space.

For example, a16z backed Genesis Therapeutics, a biotech startup using AI to accelerate drug development, reinforcing the trend of computational biology bridging the gap between biotech and tech investing.

Key Biotech Startups and Funding Trends in 2025

Several biotech startups secured blockbuster funding rounds in 2024, underscoring the renewed investor confidence in the industry. Xaira Therapeutics, a next-generation biotech company, raised a record-breaking $1 billion launch round, marking one of the largest biotech fundings of the year. This mega-deal set the tone for a wave of $100M+ early-stage biotech financings, signaling strong institutional backing for breakthrough science.

Two standout biotech startups, Seaport Therapeutics and Exsilio Therapeutics, both founded by renowned scientists with successful exits, raised Series A rounds exceeding $100–200 million each. Investors are increasingly betting on experienced biotech founders, providing them with large-scale funding from the outset to accelerate drug development and commercialization.

With biotech investment at an all-time high, a wave of AI-powered drug discovery startups, and pharmaceutical giants increasingly backing venture-stage innovation, 2025 is set to be a transformative year for biotech startups and investors.

All BioTech Investors Globally

Merus Capital

Founded

2008

Investments

Exits

Investment stage

Company profile
See full breakdown